Mazzeti, Ana LiaOliveira, Patricia Capelari deBahia, Maria TerezinhaMosqueira, Vanessa Carla Furtado2021-12-072021-12-072021MAZZETI, A. L. et al. Review on experimental treatment strategies against Trypanosoma cruzi. Journal of Experimental Pharmacology, v. 13, p. 409-432, 2021. Disponível em: <https://www.dovepress.com/review-on-experimental-treatment-strategies-against-trypanosoma-cruzi-peer-reviewed-fulltext-article-JEP>. Acesso em: 10 jun. 2021.1179-1454http://www.repositorio.ufop.br/jspui/handle/123456789/14119Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi. Currently, only nitroheterocyclic nifurtimox (NFX) and benznidazole (BNZ) are available for the treatment of Chagas disease, with limitations such as variable efficacy, long treatment regimens and toxicity. Different strategies have been used to dis cover new active molecules for the treatment of Chagas disease. Target-based and phenotypic screening led to thousands of compounds with anti-T. cruzi activity, notably the nitroheter ocyclic compounds, fexinidazole and its metabolites. In addition, drug repurposing, drug combinations, re-dosing regimens and the development of new formulations have been evaluated. The CYP51 antifungal azoles, as posaconazole, ravuconazole and its prodrug fosravuconazole presented promising results in experimental Chagas disease. Drug combina tions of nitroheterocyclic and azoles were able to induce cure in murine infection. New treatment schemes using BNZ showed efficacy in the experimental chronic stage, including against dormant forms of T. cruzi. And finally, sesquiterpene lactone formulated in nanocar riers displayed outstanding efficacy against different strains of T. cruzi, susceptible or resistant to BNZ, the reference drug. These pre-clinical results are encouraging and provide interesting evidence to improve the treatment of patients with Chagas disease.en-USabertoDrug discoveryNew chemical entitiesRepurposingDrug combinationNanomedicineArtigo publicado em periodicoThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Fonte: o PDF do artigo.https://doi.org/10.2147/JEP.S267378